Nanexa AB

Clinical trials sponsored by Nanexa AB, explained in plain language.

Nanexa AB NANEXA NASDAQ STOCKHOLM

Drug delivery company using its PharmaShell technology for injectable formulations.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

New Long-Acting diabetes shot shows promise in first human test

Disease control Completed

This early study tested a single injection of NEX-22A, a long-acting version of the diabetes drug liraglutide, in 12 adults with type 2 diabetes. The main goal was to see how the drug moves through the body and if it is safe. Participants were on stable metformin therapy and rece…

Phase 1 • Sponsor: Nanexa AB • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC

Nanexa AB

New Long-Acting diabetes shot shows promise in first human test